China
-
Eversheds Sutherland 2026 Legal Forum: The ‘real-time rewrite’ of ESG
The center of gravity for climate leadership is shifting, with China making landmark pledges and significant progress emerging from Africa, South Asia, and Eastern Europe.
-
‘I wouldn’t dare take these drugs’: how China supplies untested peptides to the west
The success of weight-loss drugs has driven demand for injectable compounds that claim to improve everything from sleep to skin.
-
Reporting obligations in corporate crime investigations
Strategies for managing crossborder reporting obligations.
-
Asia-Pacific in focus: December 2025 at a glance
Our monthly roundup of the latest developments in financial regulation from the Asia-Pacific region.
-
Bill to limit US biotech companies doing business with China advances
The new bill would have government agencies referring to the Department of Defense’s 1260H list of Chinese military companies operating in the US.
-
GRIP Extra: US bank regulators scrap leveraged lending guidance, CFTC greenlights spot crypto products
Our in-brief roundup of notable stories from the last week.
-
GRIP Extra: CME suffers 11-hour systems outage, US bank regulators ease key thresholds
Our in-brief roundup of notable stories from the last week.
-
Report to US lawmakers flags impact of China pharma on US drug supply chain
The report urges Congress to bolster US pharmaceutical supply-chain resilience and reduce dependence on China.